$920,000 of EMERGENT BIOSOLUTIONS INC lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY25 and FY26 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26 NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY25 and FY26 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26 NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY25 and FY26 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26 NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY25 and FY26 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26 NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025"
You can find more data on corporate lobbying on Quiver Quantitative.
EBS Congressional Stock Trading
Members of Congress have traded $EBS stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $EBS stock by members of Congress over the last 6 months:
- REPRESENTATIVE STEVE COHEN sold up to $15,000 on 12/11.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
EBS Insider Trading Activity
EBS insiders have traded $EBS stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $EBS stock by insiders over the last 6 months:
- DONALD W DEGOLYER sold 25,000 shares for an estimated $272,750
- NEAL FRANKLIN FOWLER sold 35,000 shares for an estimated $204,050
- MARVIN L WHITE sold 14,287 shares for an estimated $171,015
- KATHRYN C ZOON sold 10,000 shares for an estimated $57,300
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
EBS Hedge Fund Activity
We have seen 78 institutional investors add shares of EBS stock to their portfolio, and 57 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MARSHALL WACE, LLP removed 1,165,943 shares (-46.7%) from their portfolio in Q4 2024, for an estimated $11,146,415
- OAK HILL ADVISORS LP added 1,113,338 shares (+inf%) to their portfolio in Q4 2024, for an estimated $10,643,511
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC removed 934,497 shares (-42.0%) from their portfolio in Q4 2024, for an estimated $8,933,791
- MILLENNIUM MANAGEMENT LLC added 671,947 shares (+83.0%) to their portfolio in Q4 2024, for an estimated $6,423,813
- INVESCO LTD. added 638,995 shares (+70.9%) to their portfolio in Q4 2024, for an estimated $6,108,792
- GOLDMAN SACHS GROUP INC added 521,224 shares (+116.4%) to their portfolio in Q4 2024, for an estimated $4,982,901
- QUBE RESEARCH & TECHNOLOGIES LTD added 477,845 shares (+141.4%) to their portfolio in Q4 2024, for an estimated $4,568,198
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
EBS Analyst Ratings
Wall Street analysts have issued reports on $EBS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- H.C. Wainwright issued a "Buy" rating on 12/30/2024
To track analyst ratings and price targets for EBS, check out Quiver Quantitative's $EBS forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
